TY  - CONF
AU  - Arija, S. Manrique
AU  - Cabezas-Lucena, A. M.
AU  - Godoy-Navarrete, F.
AU  - Morales-Aguila, M.
AU  - Redondo, R.
AU  - Mena-Vazquez, N.
PY  - 2022
DO  - 10.1136/annrheumdis-2022-eular.445
SN  - 0003-4967
UR  - http://hdl.handle.net/10668/20053
T2  - Annals of the rheumatic diseases
AB  - Background: The long-term use of standard dosing of TNFi therapy is costly and not without side effects, including infections, tuberculosis and potential malignancies(1,2,). Hence, we undertook this study to determine whether dose reduction of TNFi...
LA  - en
PB  - BMJ Group
KW  - British society
KW  - Arthritis
KW  - Risk
KW  - Arthritis, Psoriatic
KW  - Drug Tapering
KW  - Arthritis, Rheumatoid
KW  - Axial Spondyloarthritis
KW  - Biological Therapy
KW  - Tuberculosis
KW  - Neoplasms
TI  - REAL LIFE DOSE REDUCTION OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. UTILITY OF THE REDOSER TOOL
TY  - conference output
VL  - 81
ER  -